Search

Anxiety is a common neurological disorder with high prevalence and important cause of functional impairment. Related higher cost, experience of complete remission, and intolerant response to the ongoing treatment suggest an unmet need to develop novel therapeutic strategies for the treatment of anxiety. The present review has focused on the discussion of targeting of glutamate system with melatonin or orexin or oxytocin receptors as combination approach in the treatment of anxiety. Available evidences suggest a strong correlation between glutamate system and anxiety. Melatonin, orexin, and oxytocin receptors also showed similar correlation. Recent reports suggested the functional association between melatonin and glutamate or orexin and glutamate or oxytocin and glutamate. The novel approaches discussed in present review may avail us an efficacious and safe treatment option which can be a better or alternative option for the available anxiolytic drugs. There is a need to consider combination approach targeting melatonin or orexin or oxytocin with glutamate-related receptors in different experimental settings.

As a multi-factorial degenerative disease, Parkinson's disease (PD) leads to tremor, gait rigidity, and hypokinesia, thus hampering normal living. As this disease is usually detected in the later stages when neurons have degenerated completely, cure is on hold, ultimately leading to death due to the lack of early diagnostic techniques. Thus, biomarkers are required to detect the disease in the early stages when prevention is possible. Various biomarkers providing early diagnosis of the disease include those of imaging, cerebrospinal fluid, oxidative stress, neuroprotection, and inflammation. Also, biomarkers, alone or in combination, are used in the diagnosis and evolution of PD. This review encompasses various biomarkers available for PD and discusses recent advances in their development.